Page last updated: 2024-10-26

diphenhydramine and Alcohol Abuse

diphenhydramine has been researched along with Alcohol Abuse in 11 studies

Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.

Research Excerpts

ExcerptRelevanceReference
"We created acute pancreatitis in cats by instilling ethanol (20 ml of a 40% solution) into the stomach and then perfusing activated pancreatic enzymes through the main pancreatic duct."1.28Treatment of acute alcoholic pancreatitis in cats. ( Reber, HA; Singh, SM, 1990)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19906 (54.55)18.7374
1990's1 (9.09)18.2507
2000's0 (0.00)29.6817
2010's2 (18.18)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Bogenschutz, MP2
Ross, S2
Bhatt, S1
Baron, T2
Forcehimes, AA2
Laska, E1
Mennenga, SE2
O'Donnell, K1
Owens, LT2
Podrebarac, S1
Rotrosen, J2
Tonigan, JS1
Worth, L1
O'Donnell, KC1
Podrebarac, SK1
Erbe, S1
Bschor, T1
Scanlon, KA1
Stoppacher, R1
Blum, LM1
Starkey, SJ1
Pardo, MP2
Hall, TB2
Plueckhahn, VD1
Singh, SM1
Reber, HA1
Miller, TP1
Taylor, JL1
Tinklenberg, JR1
Miller, NS1
Goodwin, DW1
Jones, FC1
Gabrielli, WF1
Anand, MM1
Guz, I2
Segre, CD1
Ribas, JC2
de Fortes, JR1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence[NCT02061293]Phase 295 participants (Actual)Interventional2014-06-30Completed
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms[NCT06160232]Phase 262 participants (Anticipated)Interventional2024-01-15Not yet recruiting
Treatment of Asian Flushing Syndrome With Topical Alpha Agonists[NCT03497442]Early Phase 120 participants (Actual)Interventional2018-07-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Drinks Per Day

The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Baseline (Week 4)

Interventiondrinks per day (Mean)
Psilocybin2.77
Diphenhydramine2.19

Drinks Per Day

The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)

Interventiondrinks per day (Mean)
Psilocybin1.17
Diphenhydramine2.26

Drinks Per Day

The Timeline Follow-back (TLFB) method is used to calculate drinks per day. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Screening (Week 0)

Interventiondrinks per day (Mean)
Psilocybin5.2
Diphenhydramine4.38

Percent of Drinking Days

The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Baseline (Week 4)

Interventionpercentage of days (Mean)
Psilocybin52.98
Diphenhydramine45.99

Percent of Drinking Days

The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)

Interventionpercentage of days (Mean)
Psilocybin29.39
Diphenhydramine42.83

Percent of Drinking Days

The Timeline Follow-back (TLFB) method is used to calculate the percentage of days that participants drank alcohol. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. (NCT02061293)
Timeframe: Screening (Week 0)

Interventionpercentage of days (Mean)
Psilocybin78.03
Diphenhydramine71.68

Percent of Heavy Drinking Days

The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Baseline (Week 4)

Interventionpercentage of days (Mean)
Psilocybin24.11
Diphenhydramine21.31

Percent of Heavy Drinking Days

The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Follow Up (Weeks 5-36)

Interventionpercentage of days (Mean)
Psilocybin9.71
Diphenhydramine23.57

Percent of Heavy Drinking Days

The Timeline Follow-back (TLFB) method is used to calculate the percent of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: Screening (Week 0)

Interventionpercentage of days (Mean)
Psilocybin56.48
Diphenhydramine48.57

Percent of Participants Achieving No Heavy Drinking Days

The Timeline Follow-back (TLFB) method is used in calculating the number of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: From Week 33 Up to Week 36

InterventionPercentage of participants (Number)
Psilocybin62.5
Diphenhydramine40

Percent of Participants Achieving No Heavy Drinking Days

The Timeline Follow-back (TLFB) method is used in calculating the number of heavy drinking days. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36

InterventionPercentage of participants (Number)
Psilocybin33.3
Diphenhydramine11.1

Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 1 Level

For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 Up to Week 36

InterventionPercentage of participants (Number)
Psilocybin89.6
Diphenhydramine64.4

Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 1 Level

For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36

InterventionPercentage of participants (Number)
Psilocybin83.3
Diphenhydramine71.1

Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 2 Levels

For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 Up to Week 36

InterventionPercentage of participants (Number)
Psilocybin60.4
Diphenhydramine40

Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 2 Levels

For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36

InterventionPercentage of participants (Number)
Psilocybin60.4
Diphenhydramine40

Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 3 Levels

For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 33 up to Week 36

InterventionPercentage of participants (Number)
Psilocybin37.5
Diphenhydramine17.8

Percent of Participants Achieving WHO Risk Drinking Level Decrease of at Least 3 Levels

For men, WHO low risk drinking (level 1) is defined as >0 grams of alcohol/day (g/d) to 40 g/d; moderate risk (level 2) as >40 g/d to 60 g/d; high risk (level 3) as >60 g/d to 100 g/d; and very high risk (level 4) as >100 g/d. For women, low risk (level 1) is defined as >0 g/d to 20 g/d; moderate risk (level 2) as >20 g/d to 40 g/d; high risk (level 3) as >40 g/d to 60 g/d; and very high risk (level 4) as >60 g/d. Abstinence was defined as no risk (level 0). (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36

InterventionPercentage of participants (Number)
Psilocybin29.92
Diphenhydramine13.3

Percentage of Participants Achieving Abstinence From Drinking

The Timeline Follow-back (TLFB) method is used in calculating abstinence from drinking. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Abstinence is defined as zero drinks of alcohol over the target period. (NCT02061293)
Timeframe: From Week 33 up to Week 36

InterventionPercentage of participants (Number)
Psilocybin47.9
Diphenhydramine24.4

Percentage of Participants Achieving Abstinence From Drinking

The Timeline Follow-back (TLFB) method is used in calculating abstinence from drinking. The TLFB is a method for assessing the number of drinks of alcohol on a daily basis over the previous 30 days. For each day in the recall period, the participant indicates the number of drinks of alcohol they consumed. The TLFB provides a calendar prompt and number of other memory aids (e.g., holidays, payday, and other personally relevant dates) to facilitate accurate recall of drug use during the target period. Abstinence is defined as zero drinks of alcohol over the target period. (NCT02061293)
Timeframe: From Week 5 (1 week after first drug administration) up to Week 36

InterventionPercentage of participants (Number)
Psilocybin22.9
Diphenhydramine8.9

Short Inventory of Problems (SIP-2R) Score

15-item self-report questionnaire assessing problems related to alcohol use. Items are ranked on a 4-point Likert scale ranging from 0 (never) to 3 (daily or almost daily). The total score range is 0-45; the higher the score, the more problems related to alcohol use. (NCT02061293)
Timeframe: Baseline (Week 4)

Interventionscore on a scale (Mean)
Psilocybin20.26
Diphenhydramine21.6

Short Inventory of Problems (SIP-2R) Score

15-item self-report questionnaire assessing problems related to alcohol use. Items are ranked on a 4-point Likert scale ranging from 0 (never) to 3 (daily or almost daily). The total score range is 0-45; the higher the score, the more problems related to alcohol use. (NCT02061293)
Timeframe: Week 36

Interventionscore on a scale (Mean)
Psilocybin6.59
Diphenhydramine13

Reviews

2 reviews available for diphenhydramine and Alcohol Abuse

ArticleYear
[Diphenhydramine addiction and detoxification. A systematic review and case report].
    Psychiatrische Praxis, 2013, Volume: 40, Issue:5

    Topics: Adult; Aged; Alcoholism; Comorbidity; Diphenhydramine; Dose-Response Relationship, Drug; Drug Admini

2013
Genetic implications of the alcohol-induced flushing phenomenon in Orientals.
    Currents in alcoholism, 1981, Volume: 8

    Topics: Acetaldehyde; Alcoholism; Asian People; Cimetidine; Diphenhydramine; Ethanol; Female; Histamine; Hum

1981

Trials

3 trials available for diphenhydramine and Alcohol Abuse

ArticleYear
Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.
    Contemporary clinical trials, 2022, Volume: 123

    Topics: Alcohol Drinking; Alcoholism; Diphenhydramine; Humans; Psilocybin; Treatment Outcome

2022
A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics.
    Neuropsychobiology, 1988, Volume: 19, Issue:2

    Topics: Adult; Alcoholism; Arousal; Attention; Diazepam; Diphenhydramine; Discrimination Learning; Humans; M

1988
Antihistamine blockade of alcohol-induced flushing in orientals.
    Journal of studies on alcohol, 1988, Volume: 49, Issue:1

    Topics: Adolescent; Adult; Alcoholism; Asian People; Blood Pressure; Cimetidine; Diphenhydramine; Ethanol; F

1988

Other Studies

6 other studies available for diphenhydramine and Alcohol Abuse

ArticleYear
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2022, 10-01, Volume: 79, Issue:10

    Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu

2022
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2022, 10-01, Volume: 79, Issue:10

    Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu

2022
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2022, 10-01, Volume: 79, Issue:10

    Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu

2022
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2022, 10-01, Volume: 79, Issue:10

    Topics: Adult; Alcohol Drinking; Alcoholism; Diphenhydramine; Double-Blind Method; Female; Hallucinogens; Hu

2022
Comprehensive Duloxetine Analysis in a Fatal Overdose.
    Journal of analytical toxicology, 2016, Volume: 40, Issue:2

    Topics: Aged; Alcoholism; Amitriptyline; Depression; Diphenhydramine; Drug Overdose; Duloxetine Hydrochlorid

2016
Alcohol and road safety: Geelong experience 1967 to 1978.
    The Medical journal of Australia, 1978, Dec-30, Volume: 2, Issue:14

    Topics: Accidents, Traffic; Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Australia; Automobile Dri

1978
Treatment of acute alcoholic pancreatitis in cats.
    Pancreas, 1990, Volume: 5, Issue:5

    Topics: Acute Disease; Alcoholism; Animals; Cats; Cimetidine; Diphenhydramine; Drug Therapy, Combination; Fe

1990
[Use of the combination methaqualone-diphenyhydramine in ambulatory patients].
    Hospital (Rio de Janeiro, Brazil), 1969, Volume: 76, Issue:6

    Topics: Adolescent; Adult; Alcoholism; Ambulatory Care; Anxiety; Diphenhydramine; Female; Humans; Male; Meth

1969
[Therapeutic test with a new non-barbiturate hypnotic].
    Hospital (Rio de Janeiro, Brazil), 1968, Volume: 73, Issue:2

    Topics: Adolescent; Adult; Alcoholism; Diphenhydramine; Humans; Hypnotics and Sedatives; Male; Mental Disord

1968